HIFU FOR
LIVER CANCER
USgHIFU delivers transcutaneous focused ultrasound ablation for HCC and liver metastases — without probe insertion, without piercing the liver capsule, and without the bleeding or pneumothorax risks of percutaneous ablation — making it accessible to patients who cannot safely undergo conventional interventional procedures.
analyticsAt a Glance
- check_circleTruly non-invasive — no probe enters the liver; acoustic energy passes through skin and abdominal wall
- check_circlePublished Chinese series: 60–80% objective response rates for HCC <5 cm treated with USgHIFU
- check_circleParticularly valuable in cirrhotic patients with coagulopathy, thrombocytopenia, or prior failed percutaneous ablation
- check_circleAccessible at specialist HAIFU centres in China via CancerFax — often combined with TACE in a multimodal protocol
Why HIFU Has a Distinct Role in Liver Cancer Treatment
Most liver cancer patients who cannot undergo resection are offered percutaneous ablation — cryoablation, RFA, or MWA — delivered through needle-sized probes inserted through the skin into the liver. This is highly effective but requires adequate coagulation, safe pleural or peritoneal access, and absence of high-risk coagulopathy. HIFU eliminates all of these requirements: no probe penetrates the liver, no coagulation is disturbed, and no incision is made.
“For a cirrhotic patient with HCC, a platelet count of 40,000, and a tumour adjacent to the gallbladder — percutaneous ablation carries real risk. HIFU treats the same tumour without touching any of it.”
The Non-Invasive Advantage in Cirrhotic Liver Disease
Advanced cirrhosis reduces platelet count, impairs coagulation, and makes the liver surface vulnerable to capsular haemorrhage from probe insertion. HIFU treats through intact skin and liver capsule — there is no puncture, no bleeding risk at the probe site, and no peritoneal contamination with tumour cells along a probe tract.
HIFU as Part of a Multimodal Liver Protocol
At Chinese hepatology centres, HIFU is most commonly used alongside TACE rather than as a standalone treatment. TACE devascularises the tumour, reduces the 'heat sink' effect of portal blood flow, and may improve HIFU penetration of previously hypervascular tumours. Sequential TACE followed by HIFU within 2–4 weeks is the standard protocol at HAIFU-equipped hepatology centres.
Key Clinical Numbers
Published Chinese USgHIFU series and the HAIFU clinical registry provide the following outcome benchmarks for liver cancer treatment.
- 60–80%Objective response rate — HCC <5 cm (HIFU alone or + TACE)Reported from HAIFU-treated HCC series; complete ablation rates highest for tumours ≤3 cm without significant vascular proximity.
- ≤5 cmOptimal HCC lesion size for HIFULesions above 5 cm require multiple sessions or combination with TACE to achieve adequate thermal dose throughout the full tumour volume.
- 2–4Typical number of HIFU treatment sessionsLarge or poorly responding tumours require multiple sessions; each session treats the target volume systematically with focal spot scanning.
- >10 cmMaximum abdominal wall thickness for acoustic windowPatients with significant ascites or very deep lesions may have insufficient acoustic access — assessed during pre-procedure planning ultrasound.
How Liver HIFU Is Performed
USgHIFU for liver tumours is performed with the patient partially submerged in a degassed water bath — the water providing acoustic coupling between the external transducer and the abdominal wall.
- 1
Pre-Procedure Assessment
Triphasic liver CT or gadoxetate MRI within 4 weeks confirms tumour dimensions, location relative to vessels and bile ducts, and absence of contraindications. Liver function tests, coagulation, and platelet count are reviewed. The acoustic window is assessed by positioning the patient and performing a planning ultrasound.
- 2
Patient Positioning in Water Bath
The patient lies prone or in lateral decubitus in a treatment tub of degassed, temperature-controlled water (34–37°C). The HIFU transducer is positioned below the water surface, directed at the liver through the abdominal wall. Respiratory gating synchronises treatment delivery to a consistent phase of the breathing cycle.
- 3
IV Sedation or General Anaesthesia
Moderate IV sedation (midazolam + fentanyl) is standard for cooperative patients. General anaesthesia allows controlled ventilation and respiratory gating — preferred for deep lesions or long treatment sessions.
- 4
Systematic Focal Ablation
The treatment console scans the focal point systematically across the pre-defined tumour volume in a grid pattern. Diagnostic ultrasound monitors the developing hyperechoic (bright) ablation zone as a real-time proxy for thermal effect. Each session treats a defined volume — typically 10–40 cm³.
- 5
Post-Treatment Assessment
Contrast-enhanced ultrasound (CEUS) is performed immediately post-treatment to assess the non-enhancing ablated volume. CT or MRI is scheduled at 4–6 weeks for formal response assessment and to plan any additional sessions.
- 6
Recovery
Patients are monitored for 2–4 hours after the procedure. Mild right upper quadrant discomfort and low-grade fever (post-ablation syndrome) are expected for 1–3 days. Discharge is same-day for uncomplicated cases.
Patient and Lesion Selection for Liver HIFU
HIFU is most appropriate when all of the following criteria are met. Cases with multiple risk factors should be reviewed at a multidisciplinary team meeting.
| Criterion | Favourable for HIFU | Caution / Less Suitable |
|---|---|---|
| Tumour size | ≤5 cm (single lesion ideal) | >5 cm — multiple sessions needed; >8 cm consider combination with TACE first |
| Tumour depth | 3–8 cm from skin surface | <3 cm (skin burn risk); >10 cm (insufficient acoustic intensity) |
| Child-Pugh score | A or B7 | B8–C — poor hepatic reserve; high risk of post-procedure decompensation |
| Coagulation | INR <2.5 acceptable | Severe coagulopathy — lower risk than percutaneous ablation but still relevant for procedural sedation |
| Acoustic window | Clear path — no bowel gas, ribs, or ascites in beam | Ascites >2 cm deep, extensive bowel gas, or deeply subcostal lesion — planning ultrasound confirms |
| Vascular proximity | ≥1 cm from major hepatic or portal vein | Perivascular lesions — heat sink effect may cause incomplete ablation; combine with TACE |
| Bile duct proximity | ≥1 cm from common bile duct / intrahepatic ducts | Central biliary proximity — biliary thermal injury risk; assess carefully |
HIFU vs Percutaneous Ablation for Liver Tumours
HIFU and percutaneous ablation (cryoablation, RFA, MWA) are complementary rather than competing for liver cancer. Patient and tumour characteristics determine which is more appropriate.
HIFU Preferred When
- Coagulopathy or thrombocytopenia is presentPlatelet count <50,000 or INR >2.0 makes percutaneous probe insertion risky — HIFU avoids puncturing the liver entirely.
- Prior failed or complicated percutaneous attemptsIf previous RFA or cryoablation was complicated by haemorrhage or was technically incomplete, HIFU provides a non-puncture alternative.
- Patient refuses or fears needle proceduresSome patients are significantly more willing to undergo non-invasive focused ultrasound than a needle procedure — concordance with the recommended treatment matters for outcome.
- Lesion adjacent to the diaphragmPercutaneous ablation of subphrenic lesions risks pleural injury and requires hydrodissection — HIFU approaches from below through the abdominal wall with no pleural contact.
Percutaneous Ablation Preferred When
- Precise real-time margin confirmation neededCryoablation's ice-ball is directly visible on CT — providing immediate margin verification HIFU cannot match with ultrasound monitoring alone.
- Perivascular lesion requiring heat-independent ablationCryoablation specifically overcomes the heat sink effect — and HIFU shares the same vulnerability to blood vessel cooling near major hepatic vessels.
- Simultaneous tissue diagnosis requiredPercutaneous ablation allows core biopsy in the same session — HIFU requires a separate biopsy procedure if histology is needed.
- Very deep lesions beyond HIFU acoustic rangeLesions at >10 cm depth may have insufficient focal intensity for reliable ablation — percutaneous approaches are depth-independent.
More from the HIFU Therapy Resource Library
Continue exploring HIFU — from the foundational science to prostate, fibroid, and bone applications.
- HIFU Therapy — Complete Treatment Guide
- What Is HIFU? Non-Invasive Focused Ultrasound Explained
- HIFU Physics: How Acoustic Focusing Destroys Tissue
- HIFU for Uterine Fibroids: MRgFUS Complete Guide
- HIFU for Prostate Cancer: Whole-Gland and Focal Treatment
- HIFU for Bone Metastases: Pain Palliation and Local Control
Frequently Asked Questions
Common questions from patients and families considering HIFU for liver cancer.
About HIFU for Liver Cancer
Can HIFU be used for liver cancer if I have significant ascites?
Moderate to severe ascites is a relative contraindication to liver HIFU — not because of safety concerns, but because ascites fluid between the abdominal wall and the liver displaces and distorts the acoustic beam, reducing the effective focal intensity at the tumour. Small-volume ascites (≤1–2 cm on ultrasound) is usually manageable with careful planning. Larger volumes should be drained before treatment is attempted. Your treating centre will perform a planning ultrasound to assess the acoustic window, including ascites status, before scheduling the procedure.
How many HIFU sessions will I need for my liver tumour?
This depends on tumour size, location, depth, and the ablation volume achievable per session. Small lesions (≤3 cm) in a favourable acoustic position may be completely treated in a single 45–60 minute session. Larger tumours (3–8 cm) or those in less accessible positions typically require 2–4 sessions spaced 1–2 weeks apart to achieve complete ablation. Each session targets a defined volume, and follow-up CEUS confirms the treated zone before the next session is planned. Your centre will give you a session estimate after the planning ultrasound.
Is HIFU effective for liver metastases from colorectal cancer?
Yes — Chinese USgHIFU centres have published series treating liver metastases from colorectal, gastric, breast, and other primaries alongside or instead of percutaneous ablation. The eligibility criteria and procedural approach are the same as for HCC. HIFU for colorectal liver metastases is most effective as part of a multimodal strategy — systemic chemotherapy (FOLFOX/FOLFIRI) addresses the systemic disease while HIFU provides local control of individual hepatic lesions. CancerFax can assess whether your specific metastatic burden and pattern makes you a candidate for this combined approach at Chinese centres.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Assess Whether HIFU Is Right for Your Liver Cancer
CancerFax reviews your liver imaging, Child-Pugh score, tumour characteristics, and treatment history to determine whether USgHIFU is appropriate — and connects you with specialist hepatology HIFU centres in China experienced in treating HCC and liver metastases.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.